Correlation Between ADC Therapeutics and Corvus Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both ADC Therapeutics and Corvus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ADC Therapeutics and Corvus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between ADC Therapeutics SA and Corvus Pharmaceuticals, you can compare the effects of market volatilities on ADC Therapeutics and Corvus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ADC Therapeutics with a short position of Corvus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of ADC Therapeutics and Corvus Pharmaceuticals.

Diversification Opportunities for ADC Therapeutics and Corvus Pharmaceuticals

-0.36
  Correlation Coefficient

Very good diversification

The 3 months correlation between ADC and Corvus is -0.36. Overlapping area represents the amount of risk that can be diversified away by holding ADC Therapeutics SA and Corvus Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Corvus Pharmaceuticals and ADC Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ADC Therapeutics SA are associated (or correlated) with Corvus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Corvus Pharmaceuticals has no effect on the direction of ADC Therapeutics i.e., ADC Therapeutics and Corvus Pharmaceuticals go up and down completely randomly.

Pair Corralation between ADC Therapeutics and Corvus Pharmaceuticals

Given the investment horizon of 90 days ADC Therapeutics SA is expected to under-perform the Corvus Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, ADC Therapeutics SA is 1.07 times less risky than Corvus Pharmaceuticals. The stock trades about -0.05 of its potential returns per unit of risk. The Corvus Pharmaceuticals is currently generating about 0.31 of returns per unit of risk over similar time horizon. If you would invest  404.00  in Corvus Pharmaceuticals on August 31, 2024 and sell it today you would earn a total of  538.00  from holding Corvus Pharmaceuticals or generate 133.17% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

ADC Therapeutics SA  vs.  Corvus Pharmaceuticals

 Performance 
       Timeline  
ADC Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ADC Therapeutics SA has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Corvus Pharmaceuticals 

Risk-Adjusted Performance

24 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Corvus Pharmaceuticals are ranked lower than 24 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Corvus Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

ADC Therapeutics and Corvus Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with ADC Therapeutics and Corvus Pharmaceuticals

The main advantage of trading using opposite ADC Therapeutics and Corvus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ADC Therapeutics position performs unexpectedly, Corvus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corvus Pharmaceuticals will offset losses from the drop in Corvus Pharmaceuticals' long position.
The idea behind ADC Therapeutics SA and Corvus Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Other Complementary Tools

Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets